Acadia Pharmaceuticals receives positive CHMP opinion for DAYBU
Acadia Pharmaceuticals (NASDAQ:ACAD) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older.

_1428852_640x360_2504840259789-640x360.webp&w=3840&q=75)



_1428827_640x360_2504837699943-640x360.webp&w=3840&q=75)
_1428816_640x360_2504837699931-640x360.webp&w=3840&q=75)
_1428798_640x360_2504836675679-640x360.webp&w=3840&q=75)



